Method for stimulating weight loss and/or for lowering triglycerides in patients

Abstract

Administration of a therapeutically effective amount of 3,5-diiodothyropropionic acid stimulates weight loss in patients, lowers triglyceride levels and reduces risk of death or progression of coronary heart disease in patients with metabolic syndrome.

1 - 29 . (canceled) 
   
   
       30 . A method of reducing risk of death or progression of coronary heart disease in patients with metabolic syndrome comprising administering to the patient a therapeutically effective amount of 3,5-diiodothyropropionic acid. 
   
   
       31 . The method of  claim 30 , wherein 3,5-diiodothyropropionic acid is administered as a formulation selected from the group consisting of a liquid preparation, a solid preparation, a capsule preparation, and an implant preparation. 
   
   
       32 . The method of  claim 31 , wherein said formulation further comprises a pharmaceutically acceptable carrier. 
   
   
       33 . The method of  claim 32 , wherein said formulation further comprises at least one of a stabilizer, an excipient, a solubilizer, an antioxidant, a pain-alleviating agent, and an isotonic agent. 
   
   
       34 . The method of  claim 30 , wherein said 3,5-diiodothyropropionic acid is administered by parenteral injection. 
   
   
       35 . The method of  claim 34 , wherein said 3,5-diiodothyropropionic acid is administered by parenteral intravenous injection. 
   
   
       36 . The method of  claim 30 , wherein said 3,5-diiodothyropropionic acid is administered orally. 
   
   
       37 . The method of  claim 30 , wherein said 3,5-diiodothyropropionic acid is administered directly to the pulmonary system of the patient. 
   
   
       38 . The method of  claim 30 , wherein said 3,5-diiodothyropropionic acid is administered transdermally. 
   
   
       39 . The method of  claim 30 , wherein said 3,5-diiodothyropropionic acid is administered by implantation. 
   
   
       40 . The method of  claim 30 , wherein said 3,5-diiodothyropropionic acid is administered at a daily dosage of 0.1 to 10.0 mg/kg. 
   
   
       41 . The method of  claim 40 , wherein said daily dosage is from 1.875 to 3.75 mg/kg. 
   
   
       42 . The method of  claim 30 , wherein said 3,5-diiodothyropropionic acid is administered with a conventional lipid/triglyceride lowering therapeutic agent. 
   
   
       43 . A method of treating patients with metabolic syndrome comprising administering to the patient a therapeutically effective amount of 3,5-diiodothyropropionic acid. 
   
   
       44 . The method of  claim 43 , wherein 3,5-diiodothyropropionic acid is administered as a formulation selected from the group consisting of a liquid preparation, a solid preparation, a capsule preparation, and an implant preparation. 
   
   
       45 . The method of  claim 44 , wherein said formulation further comprises a pharmaceutically acceptable carrier. 
   
   
       46 . The method of  claim 43 , wherein said formulation further comprises at least one of a stabilizer, an excipient, a solubilizer, an antioxidant, a pain-alleviating agent, and an isotonic agent. 
   
   
       47 . The method of  claim 43 , wherein said 3,5-diiodothyropropionic acid is administered by parenteral injection. 
   
   
       48 . The method of  claim 47 , wherein said 3,5-diiodothyropropionic acid is administered by parenteral intravenous injection. 
   
   
       49 . The method of  claim 43 , wherein said 3,5-diiodothyropropionic acid is administered orally. 
   
   
       50 . The method of  claim 43 , wherein said 3,5-diiodothyropropionic acid is administered directly to the pulmonary system of the patient. 
   
   
       51 . The method of  claim 43 , wherein said 3,5-diiodothyropropionic acid is administered transdermally. 
   
   
       52 . The method of  claim 43 , wherein said 3,5-diiodothyropropionic acid is administered by implantation. 
   
   
       53 . The method of  claim 43 , wherein said 3,5-diiodothyropropionic acid is administered at a daily dosage of 0.1 to 10.0 mg/kg. 
   
   
       54 . The method of  claim 53 , wherein said daily dosage is from 1.875 to 3.75 mg/kg. 
   
   
       55 . The method of  claim 43 , wherein said 3,5-diiodothyropropionic acid is administered with a conventional lipid/triglyceride lowering therapeutic agent.